相关实验视频

Updated: Jul 21, 2025

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

一个可解释的放射基因组框架来预测肺腺癌患者中KRAS和EGFR的突变状态

Berardino Prencipe¹, Claudia Delprete¹, Emilio Garolla²

¹Department of Electrical and Information Engineering, Polytechnic University of Bari, Via Orabona 4, 70126 Bari, Italy.

Bioengineering (Basel, Switzerland)

|July 29, 2023

概括

来自CT扫描的放射性特征可以预测肺腺癌中的KRAS和EGFR突变. 这种放射遗传学方法有助于理解瘤遗传学,以改善预后和治疗策略.

科学领域:

在瘤学瘤学.
放射学放射学是一门学科.
基因组学就是基因组学.

背景情况:

肺腺癌的复杂病理生物学需要先进的诊断工具.
早期识别KRAS和EGFR突变对于预后和治疗反应至关重要.

研究的目的:

开发一个放射基因组工作流程,用于检测肺腺癌中的KRAS和EGFR突变,使用CT衍生的放射性特征.
识别显著的放射性特征,并评估用于预测突变状态的分类模型.

主要方法:

从肺腺癌患者的计算机断层扫描 (CT) 图像中提取了放射性特征.
采用特征选择算法和分类模型 (包括多层感知器).
使用SHAP (夏普利添加式扩展) 进行特征解释.

主要成果:

在验证集上,EGFR的AUC达到0.69和KRAS突变预测的AUC为0.82.
多层感知器模型在两种突变中都表现出卓越的性能.
在特定的放射性特征和EGFR/KRAS突变状态之间建立了关联.

结论:

放射基因组分析对非侵入性预测肺腺癌中关键遗传变化的有希望.
这种方法可以通过基于瘤遗传学的治疗决策来支持个性化医疗.
进一步验证是有必要的,以整合这个放射基因组工作流程到临床实践.

关键词:

这就是为什么CTCTCTCTCTCT 欧洲农业基金会 (EGFR) 是一个.克拉斯 (Kras) 是一个国家.可以解释性的解释性.肺部腺癌的癌症.辐射基因组学辐射基因组学

更多相关视频

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

相关概念视频

The Ras Gene

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...

Mutagenicity and Carcinogenicity

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...